Neuronal Damage In Delirium Study

NCT03724201 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2023-12-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate associations between neuronal damage biomarkers (S100 calcium-binding protein beta \[S-100β\], neuron-specific enolase \[NSE\], ubiquitin carboxy-terminal hydrolase L1 \[UCHL1\], and brain-derived neurotropic factor \[BDNF\]) and delirium severity and subsyndromal delirium in a homogeneous population of mechanically ventilated patients with sepsis.

Conditions

  • Delirium

Sponsors & Collaborators

  • University of Calgary

    lead OTHER

Principal Investigators

  • Kirsten M Fiest, PhD · University of Calgary

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-30
Primary Completion
2019-05-01
Completion
2019-05-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03724201 on ClinicalTrials.gov